In Brief: Genzyme
This article was originally published in The Gray Sheet
Executive Summary
Genzyme: Launches its N-geneous high-density lipoprotein cholesterol test in the U.S. following recent FDA 510(k) clearance of the assay. Run on automated equipment, the system "eliminates the need to pretreat patient samples manually," providing "significant operational benefits" and "reducing the probability of error," Genzyme says in an Oct. 17 release. Estimating the U.S. market for the N-geneous device at 50-100 mil. tests per year, the company is marketing the system as a "replacement for current HDL cholesterol tests, which are often run in conjunction with total cholesterol testing." Under a deal with Japanese manufacturer Daiichi Pure Chemicals Co., Genzyme has worldwide distribution rights to the test, which has been available in international markets, excluding Asia, since June...
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.